Raiffeisen Bank International AG Has $1.15 Million Stock Holdings in Evolent Health, Inc (NYSE:EVH)

Key Points

• Raiffeisen Bank International AG increased its stake in Evolent Health by 33.3%, now owning 120,000 shares valued at approximately $1.15 million.
• Evolent Health reported a quarterly revenue of $483.65 million, which surpassed analysts' expectations, even though its earnings per share of $0.06 missed estimates by $0.02.
• Analysts maintain a positive outlook on Evolent Health, with an average rating of "Buy" and a consensus target price of $17.93 per share.

Raiffeisen Bank International AG lifted its holdings in shares of Evolent Health, Inc (NYSE:EVH - Free Report) by 33.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 120,000 shares of the technology company's stock after acquiring an additional 30,000 shares during the period. Raiffeisen Bank International AG owned approximately 0.10% of Evolent Health worth $1,152,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banque Cantonale Vaudoise bought a new position in shares of Evolent Health during the 1st quarter worth about $25,000. US Bancorp DE lifted its holdings in shares of Evolent Health by 291.0% during the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock worth $49,000 after acquiring an additional 3,835 shares during the period. Signaturefd LLC lifted its holdings in shares of Evolent Health by 400.6% during the 1st quarter. Signaturefd LLC now owns 7,043 shares of the technology company's stock worth $67,000 after acquiring an additional 5,636 shares during the period. GAMMA Investing LLC grew its holdings in shares of Evolent Health by 5,036.4% in the 1st quarter. GAMMA Investing LLC now owns 9,451 shares of the technology company's stock worth $90,000 after purchasing an additional 9,267 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Evolent Health in the 4th quarter worth about $95,000.

Evolent Health Trading Down 7.1%

Evolent Health stock traded down $0.69 during trading hours on Friday, reaching $9.00. 6,353,440 shares of the company's stock traded hands, compared to its average volume of 2,283,437. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.98 and a current ratio of 0.98. Evolent Health, Inc has a fifty-two week low of $7.06 and a fifty-two week high of $33.63. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -5.59 and a beta of 0.82. The firm's 50 day moving average is $9.93 and its 200-day moving average is $9.64.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.78%. The business had revenue of $444.33 million for the quarter, compared to analyst estimates of $459.43 million. During the same quarter in the previous year, the company posted $0.30 earnings per share. The business's revenue for the quarter was down 31.3% on a year-over-year basis. On average, analysts predict that Evolent Health, Inc will post 0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EVH. UBS Group upped their target price on shares of Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Truist Financial upped their target price on shares of Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a report on Tuesday, May 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $13.00 target price on shares of Evolent Health in a report on Friday, June 20th. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $17.93.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.